A bile acid the body already makes, sold as a supplement. Here is what it does, what the research says, and where the evidence runs out.
TUDCA stands for tauroursodeoxycholic acid. It is a bile acid that the human liver produces in small amounts as part of its normal bile pool. It is not a plant extract, not a vitamin, and not a new discovery. It has been present in the hepatology literature for decades, studied mostly in the context of liver conditions and bile duct disease.
In the UK it is available over the counter as a food supplement. What follows is a plain account of what it is, how it works, what the published research actually found, and where the limits of that evidence sit.
A conjugated bile acid
The liver makes bile acids and conjugates them — attaches either a taurine or a glycine group — before secreting them into the bile ducts. TUDCA is ursodeoxycholic acid (UDCA) with a taurine group attached. That is the entire chemical difference between the two.
UDCA itself has been used in medicine for decades. It is a prescription-only drug in the UK, used in primary biliary cholangitis and for dissolving cholesterol gallstones. Because TUDCA is the taurine-conjugated form — the form the liver would produce anyway — it is classified as a food supplement rather than a medicine, and can be sold without a prescription.
This distinction matters. It means TUDCA is available to people who would not meet the diagnostic threshold for a UDCA prescription, but it also means it has not been through the same regulatory approval process as a licensed drug.
The bile flow mechanism
Bile is a surfactant. Its mechanical job is to take large fat droplets in the small intestine and break them into microscopic ones, so that pancreatic lipase can reach and digest them. For this to work, bile has to arrive in sufficient volume at roughly the moment food enters the duodenum.
When bile thickens or flow becomes sluggish, that emulsification step underperforms. Fats that are not broken down upstream pass into the lower gut largely intact, where gut bacteria ferment them, producing gas and the bloating that follows.
TUDCA is hydrophilic — it favours water over fat. Adding a hydrophilic bile acid to the bile pool shifts its overall composition toward thinner, more free-flowing bile. That is the mechanical case for supplementation, stated at its plainest: it supports the composition of the bile pool and, by extension, supports fat digestion.
This is a physiological argument, not a clinical claim. It describes what the compound does in the body. Whether that translates into a noticeable difference for any given person depends on whether sluggish bile flow was their actual bottleneck, and no test short of trying it will answer that question.
The chemical chaperone mechanism
The most-cited mechanism for TUDCA in the research literature has nothing to do with digestion. It concerns protein folding.
The endoplasmic reticulum is the part of the cell where newly made proteins are folded into their working shapes. Under stress — from toxins, inflammation, or metabolic strain — that machinery falters and misfolded proteins accumulate. The cell responds with a cascade called the Unfolded Protein Response, which, if it persists, can trigger cell death.
In laboratory studies, TUDCA has been shown to act as a chemical chaperone: a small molecule that helps stabilise protein folding and reduce endoplasmic reticulum stress. This is a real and well-characterised mechanism, reproduced across multiple cell and animal models.
The qualification is important. Most of this work is in cells and in mice. The human evidence for the chaperone effect at supplement doses is thin, and extrapolating from a mouse liver to a human one is the oldest trap in nutrition science. The mechanism exists. The size of the effect in a living person taking 500 mg a day is not established.
What the clinical research found
The strongest single piece of evidence is a randomised controlled trial: Ma et al., 2016, with 199 patients over 24 weeks. One arm received TUDCA at 750 mg a day, the other received UDCA at the same dose, for a liver condition. On the primary endpoint the two were statistically equivalent — 75.97 percent against 80.88 percent, P = 0.453. Adverse events were similar in both arms, 44 percent against 40 percent, with 93.80 percent judged unrelated to the study drug, and no serious adverse events reported in either group.
A separate case series followed 33 patients given TUDCA orally at 500 to 750 mg a day for three to twelve months. Its value is narrow: it establishes that these doses have been given to people for extended periods.
What the literature does not contain is a trial of TUDCA in otherwise healthy people with sluggish digestion, fat-triggered bloating, or post-cholecystectomy discomfort. The physiological reasoning is sound, but the population-specific evidence does not yet exist. Anyone who tells you otherwise is extrapolating.
Who considers it
The people who tend to look into TUDCA fall into a few broad groups. People who have had their gallbladder removed and find that fat digestion has changed — the timing of bile delivery is disrupted, and the symptoms can appear weeks or years after surgery. People with fat-triggered bloating whose scans and blood tests are clear, who have cycled through probiotics and enzymes without improvement. Athletes on calorie-dense, high-fat training diets who want to support bile flow under heavy nutritional demand. And people on high-fat diets more generally — keto, carnivore — who notice digestive discomfort as fat intake rises.
None of these groups has a dedicated clinical trial to point to. The reasoning from physiology is straightforward, and the safety data from adjacent populations is reassuring, but the honest position is that this is a plausible intervention, not a proven one.
How it is taken
The standard serving is two capsules — 500 mg total — taken together with the largest meal of the day. Not split across two meals, and not on an empty stomach, because bile is called for when fat arrives in the duodenum and rapid transit on an empty stomach can cause discomfort.
Some people experience loose stools or mild cramping in the first few days. This is not a detox event or a healing crisis. It is a normal short-term response to a shift in bile pool composition, and it usually settles within the first week. If it does not, it is worth speaking to a pharmacist.
What it is not
TUDCA is not a cure for anything. It is a food supplement that supports bile flow and has been studied for its effects on the bile pool and on cellular stress. It is not a replacement for medical advice or for any prescription. It is not suitable during pregnancy or breastfeeding, or for anyone under 18. Anyone taking prescription medication, or under care for a liver, bile duct, bowel or heart condition, should speak to a GP or pharmacist before starting.
A pharmacist can rule it in or out in about a minute. That conversation is a better use of time than any amount of reading.